FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. SERIAL NO. USB95AR CNR KDR

APPLICANT

Jean PLOUET et al.

(37 CFR 1.98(b)				FILING DATE June 22, 1998			GROUP 1644	
-			U.S. PAT	ENT DOCUMENTS	L			
EXAMINER INITIAL	_	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AA				_	•		
	AB							
	AC							
	AD					_		
	AE						·	
	AF							
	AG							
	FOI	REIGN PATENT O	R PUBLIS	HED FOREIGN PATEN	IT APP	LICATION	1	
		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO	
189	AL	0 502 416	9/92	Europe			yes	
138	АМ	WO 94/11499	5/94	International			yes	
	AN							
	AO						<u> </u>	
	AP							
OTHER Publica			ng Auth	or, Title, Date, Re	elevant	Pages	, Place of	
182	AR	by Plouet et al., "VEGF Dependent Tumoral Progression: Stimulation by Anti VEGF Idiotypic Antibodies", <u>JOURNAL OF CELLULAR BIOCHEMISTRY</u> , Supplement 18A, 1994, page 328.						
139	AS	by Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor", <u>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICA-TIONS</u> , Vol. 187, No. 3, 1992, pages 1579-1586.						
SER	AT	by Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis", CELL, Vol. 72, 1993, pages 835-846						
EXAMI	NER			DATE CONSIDE	RED			

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b)

ATTY. DOCKET NO.	SERIAL NO.
USB95AR CNR KDR	5ERIAL NO. 09/091,5%
APPLICANT	

Jean PLOUET et al.

FILING DATE June 22, 1998 **GROUP** 1644

U.S. PATENT DOCUMENTS ISSUE EXAMINER SUB FILING DATE INITIAL PATENT NUMBER DATE **PATENTEE** CLASS **CLASS** IF APPROPRIATE AA AB AC AD AE AF AG AΗ FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION PUBL. SUB **TRANSLATION** YES NO **CLASS** DOCUMENT NO. DATE COUNTRY OR PATENT OFFICE CLASS AL AM AN AO AP OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of **Publication**) by Millauer et al., "Glioblastoma Growth Inhibited in vivo AR by a Dominant-Negative Flk-1 Mutant", NATURE, Vol. 367, 1994, pages 576-579. AS by Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo", NATURE, Vol. 362, 1993, pages 841-844. by Chagnaud et al., "Curative Effects on Rat Sarcomas Obtained After a Treatment Combining Two Monoclonal Antibodies", ANTI-CANCER DRUGS, Vol. 5, 1994, pages 361-366. **EXAMINER DATE CONSIDERED** Eweld

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. USB95AR CNR KDR SERIAL NO.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b)

APPLICANT Jean PLOUET et al.

FILING DATE

GROUP

1644 June 22, 1998 **U.S. PATENT DOCUMENTS** EXAMINER ISSUE SUB FILING DATE INITIAL PATENT NUMBER DATE **PATENTEE CLASS CLASS** IF APPROPRIATE AA AB AC AD AE AF AG AH ΑI FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION PUBL. SUB TRANSLATION YES NO DOCUMENT NO. DATE **COUNTRY OR PATENT OFFICE** CLASS CLASS AL AM AN AO AP OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) by Ortega et al., "Modulation de la Progression Tumoral AR par des Anticorps Anti-Idiotypiques de Facteurs Translation Angiogeniques", C.R. ACAD. SCI. PARIS, SCIENCE DE Vol. 319, 1996, pages 411-415. Abeliact AS **AT DATE CONSIDERED EXAMINER** Fwoldt

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4/26/00